Utility of CAML as Diagnostic for Early Stage Lung Cancer

Active, not recruitingOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

May 21, 2019

Primary Completion Date

November 14, 2022

Study Completion Date

November 30, 2025

Conditions

Pulmonary Nodule, MultiplePulmonary Nodule, Solitary

Trial Locations (2)

Corporal Michael J. Crescenz VA Medical Center, Philadelphia

Fox Chase Cancer Center, Philadelphia

All Listed Sponsors

collaborator

United States Department of Defense

FED

collaborator

Creatv Microtech, Inc.

OTHER

lead

Fox Chase Cancer Center

OTHER

NCT03992183 - Utility of CAML as Diagnostic for Early Stage Lung Cancer | Biotech Hunter | Biotech Hunter